Detection of thyroid cancer by an FDG-PET cancer screening program: A Japanese nation-wide survey

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4439-4446

  Minamimoto, Ryogo ^a,f   Senda, Michio ^b   Jinnouchi, Seishi ^c   Terauchi, Takashi ^d   Yoshida, Tsuyoshi ^e   Inoue, Tomio ^f  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c Atsuchi Memorial Clinic PET Center   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e Koga Hospital 21   (Japan)

^f YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Japan; PET; PET CT; Screening; Thyroid cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADENOMATOID TUMOR; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; HEALTH CARE SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NODULAR GOITER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SENSITIVITY ANALYSIS; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDITIS; VERY ELDERLY; EARLY DIAGNOSIS; METHODOLOGY; PET; PET/CT; SCINTISCANNING; SCREENING; THYROID TUMOR;

JAPAN; PET; PET/CT; SCREENING; THYROID CANCER;

ADULT; EARLY DETECTION OF CANCER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84908696206     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. GLOBOCAN. Estimated cancer Incidence, Mortality and Prevalence World Wide in 2012. 2012. http://globocan.iarc.fr/fact-sheet-cancer.aspx.
2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N and Zhang Y: International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20: 525-531, 2009.
3. Han MA, Choi KS, Lee HY, Kim Y, Jun JK and Park EC: Current status of thyroid cancer screening in Korea: results from a nationwide interview survey. Asian Pac J Cancer Prev 12: 1657-1663, 2011.
4. Tan GH and Gharib H: Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126: 226-231, 1997.
5. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI and Tessler FN: Society of Radiologists in Ultrasound. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237: 794-800, 2005.
6. Desser TS and Kamaya A: Ultrasound of thyroid nodules. Neuroimaging Clin N Am 18: 463-478, 2008.
7. Bramley MD and Harrison BJ: Papillary microcarcinoma of the thyroid gland. Br J Surg 83: 1674-1683,1996.
8. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K and Miyauchi A: An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13: 381-387, 2003.
9. Ross DS: Nonpalpable thyroid nodules - managing an epidemic. J Clin Endocrinol Metab 87: 1938-1940, 2002.
10. Miki H, Inoue H, Komaki K, Uyama T, Morimoto T and Monden Y: Value of mass screening for thyroid cancer. World J Surg 22: 99-102, 1998.
11. Suehiro F: Thyroid cancer detected by mass screening over a period of 16 years at a health care center in Japan. Surg Today 36: 947-953, 2006.
12. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM and Moley JF: Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130: 941-946, 2001.
13. Chu QD, Connor MS, Lilien DL, Johnson LW, Turnage RH and Li BD: Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 72: 272-275, 2006.
14. Chen YK, Ding HJ, Chen KT, Chen YL, Liao AC, Shen YY, Su CT and Kao CH: Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 25: 1421-1426, 2005.
15. 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88: 4100-4104, 2003.
16. Van den Bruel A, Maes A, De Potter T, Mortelmans L, Drijkoningen M, Van Damme B, Delaere P and Bouillon R: Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 87: 1517-1520, 2002.
17. Minamimoto R, Senda M, Jinnouchi S, Terauchi T, Yoshida T, Murano T, Fukuda H, Iinuma T, Uno K, Nishizawa S, Tsukamoto E, Iwata H, Inoue T, Oguchi K, Nakashima R and Inoue T: The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey. Ann Nucl Med 27: 46-57, 2013.
18. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI and Tuttle RM: American Thyroid Association Guidelines Taskforce.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109-142, 2006.
19. Laure Giraudet A, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E and Schlumberger M: Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158: 239-246, 2008.
20. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P and Pinchera A: Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 78: 826-829, 1994.
21. Wilhelm SM, Robinson AV, Krishnamurthi SS and Reynolds HL: Evaluation and management of incidental thyroid nodules in patients with another primary malignancy. Surgery 142: 581-586, 2007.
22. Ishigaki S, Shimamoto K, Satake H, Sawaki A, Itoh S, Ikeda M, Ishigaki T and Imai T: Multi-slice CT of thyroid nodules: comparison with ultrasonography. Radiat Med 22: 346-353, 2004.
23. Shie P, Cardarelli R, Sprawls K, Fulda KG and Taur A: Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 30: 742-748, 2009.
24. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA and Goellner JR: Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130: 1028-1034, 2001.
25. Cronan JJ: Thyroid nodules: is it time to turn off the US machines? Radiology 247: 602-604, 2008.
26. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK and O'Sullivan B: A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 79: 2414-2423, 1997.
27. Lang BH, Lo CY, Chan WF, Lam KY and Wan KY: Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245: 366-378, 2007.
28. Loh KC, Greenspan FS, Gee L, Miller TR and Yeo PP: Pathological tumor-node- metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82: 3553-3562, 1997.
29. Lundgren CI, Hall P, Dickman PW and Zedenius J: Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106: 524-531, 2006.
30. Ito Y, Miyauchi A, Jikuzono T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Ichihara K and Kuma K: Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. World J Surg 31: 838-848, 2007.
31. Wada N, Nakayama H, Suganuma N, Masudo Y, Rino Y, Masuda M and Imada T: Prognostic value of the sixth edition AJCC/UICC TNM classification for differentiated thyroid carcinoma with extrathyroid extension. J Clin Endocrinol Metab 92: 215-218, 2007.
32. Lang B, Lo CY, Chan WF, Lam KY and Wan KY: Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability Ann Surg Oncol 14: 1551-1559, 2007.
33. Kupferman ME, Weinstock YE, Santillan AA, Mishra A, Roberts D, Clayman GL and Weber RS: Predictors of level V metastasis in well-differentiated thyroid cancer. Head Neck 30: 1469-1474, 2008.
34. Sato N, Oyamatsu M, Koyama Y, Emura I, Tamiya Y and Hatakeyama K: Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? J Surg Oncol 69: 151-155, 1998.
35. Turanli S: Is the type of dissection in lateral neck metastasis for differentiated thyroid carcinoma important? Otolaryngol Head Neck Surg 136: 957-960, 2007.
36. Murano T, Minamimoto R, Senda, Uno K, Jinnouchi S, Fukuda H, Iinuma T, Tsukamoto E, Terauchi T, Yoshida T, Oku S, Nishizawa S, Ito K, Oguchi K, Kawamoto M, Nakashima R, Iwata H and Inoue T: Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: Results of a Japanese nationwide survey. Ann Nucl Med 25: 657-666, 2011.